Sanofi
SAN
Rang în acțiuni
#225
Sanofi is a global healthcare enterprise dedicated to the research,... Sanofi is a global healthcare enterprise dedicated to the research, development, manufacturing, and commercialization of therapeutic solutions across the United States, Europe, and other international markets. Its business is structured into three primary divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. The Pharmaceuticals segment delivers specialized treatments, encompassing human monoclonal antibodies and therapies for a range of conditions such as multiple sclerosis, neurological disorders, various inflammatory and immunological diseases, rare disorders, oncology, and rare blood conditions. This division also provides medications for diabetes, cardiovascular health, and a portfolio of established prescription drugs. Through its Vaccines division, Sanofi supplies crucial immunizations, including pediatric vaccines for diseases like poliomyelitis, pertussis, and Hib, alongside adult vaccines addressing influenza, booster needs, meningitis, and those required for travel or endemic regions. The Consumer Healthcare portfolio features over-the-counter remedies for common ailments such as allergies, coughs and colds, and pain relief. It also includes products for liver care, general physical and mental wellness, probiotics, digestive health, and nutritional support. Additionally, this segment offers personal care items like daily body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and powders for eczema. Sanofi maintains an active pipeline with numerous pharmaceutical products and vaccines currently undergoing various stages of development. The company has forged strategic alliances, including a collaboration with GlaxoSmithKline for the development of a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine aimed at advancing immunology and inflammation knowledge, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company operated as Sanofi-Aventis before rebranding to Sanofi in May 2011.
Preț acțiune
$83.84
Capitalizare de piață
$100.45B
Schimbare (1 zi)
1.48%
Schimbare (1 an)
-16.74%
Țară
FR
Tranzacționează Sanofi (SAN)
Categorie
Healthcare
Raport P/E pentru Sanofi (SAN)
Raport P/E la data de October 2026 TTM: 22.92
Conform celor mai recente rapoarte financiare și prețului acțiunilor Sanofi, raportul P/E actual (TTM) este 22.92. La sfârșitul anului 2024, compania avea un P/E de 21.10.
Istoricul raportului P/E pentru Sanofi din 2001 până în 2026
Raportul P/E la sfârșitul fiecărui an
| An | Raport P/E | Schimbă |
|---|---|---|
| 2026 (TTM) | 22.92 | 77.27% |
| 2025 | 12.93 | -38.74% |
| 2024 | 21.10 | 1.40% |
| 2023 | 20.81 | 54.85% |
| 2022 | 13.44 | -24.64% |
| 2021 | 17.83 | 122.16% |
| 2020 | 8.02 | -80.27% |
| 2019 | 40.67 | 85.62% |
| 2018 | 21.91 | 104.46% |
| 2017 | 10.72 | -48.99% |
| 2016 | 21.01 | -12.27% |
| 2015 | 23.95 | 5.61% |
| 2014 | 22.68 | -17.41% |
| 2013 | 27.46 | 42.49% |
| 2012 | 19.27 | 46.27% |
| 2011 | 13.18 | -8.09% |
| 2010 | 14.34 | 4.92% |
| 2009 | 13.66 | 65.17% |
| 2008 | 8.27 | -48.59% |
| 2007 | 16.09 | -32.21% |
| 2006 | 23.74 | -45.86% |
| 2005 | 43.84 | -317.87% |
| 2004 | -20.12 | -199.40% |
| 2003 | 20.24 | -15.94% |
| 2002 | 24.08 | -37.41% |
| 2001 | 38.47 | 0.00% |
Raportul P/E pentru companii similare sau concurenți
| Companie | P/E Ratio | Diferență P/E Ratio | Țara |
|---|---|---|---|
| 43.73 | 90.79% |
US
|
|
| 39.77 | 73.51% |
US
|
|
| 80.21 | 249.97% |
US
|
|
| 121.17 | 428.64% |
US
|
|
| 25.53 | 11.37% |
CH
|
Cum interpretezi un P/E ratio?
Raportul Preț/Câștig (P/E Ratio) măsoară relația dintre prețul acțiunii unei companii și câștigul pe acțiune.
Un P/E scăzut dar pozitiv indică o companie cu profituri mari în raport cu evaluarea actuală și ar putea fi subevaluată. Un P/E negativ mare (aproape de 0) indică pierderi majore.
Companiile cu un P/E peste 30 sau negativ sunt considerate în general „acțiuni de creștere”, adică investitorii se așteaptă la creștere sau profitabilitate viitoare.
Companiile cu un P/E pozitiv sub 10 sunt considerate „acțiuni de valoare”, adică sunt deja profitabile, dar cu șanse mici de creștere suplimentară.